NO961536L - Preparation of bisphosphonates and growth hormone secretagogue - Google Patents

Preparation of bisphosphonates and growth hormone secretagogue

Info

Publication number
NO961536L
NO961536L NO961536A NO961536A NO961536L NO 961536 L NO961536 L NO 961536L NO 961536 A NO961536 A NO 961536A NO 961536 A NO961536 A NO 961536A NO 961536 L NO961536 L NO 961536L
Authority
NO
Norway
Prior art keywords
bisphosphonates
growth hormone
preparation
hormone secretagogue
secretagogue
Prior art date
Application number
NO961536A
Other languages
Norwegian (no)
Other versions
NO961536D0 (en
Inventor
Barry J Gertz
Gideon A Rodan
Roy G Smith
Matthew J Wyvratt
Arthur A Patchett
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO961536D0 publication Critical patent/NO961536D0/en
Publication of NO961536L publication Critical patent/NO961536L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Bisfosfonater i kombinasjon med veksthormonsekretagoga reduserer de skadelige effektene av osteoporose hos eldre pasienter.Bisphosphonates in combination with growth hormone secretagogue reduce the deleterious effects of osteoporosis in elderly patients.

NO961536A 1993-10-19 1996-04-18 Preparation of bisphosphonates and growth hormone secretagogue NO961536L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13929693A 1993-10-19 1993-10-19
US25909194A 1994-06-13 1994-06-13
PCT/US1994/011912 WO1995011029A1 (en) 1993-10-19 1994-10-18 Combination of bisphosphonates and growth hormone secretagogues

Publications (2)

Publication Number Publication Date
NO961536D0 NO961536D0 (en) 1996-04-18
NO961536L true NO961536L (en) 1996-06-18

Family

ID=26837073

Family Applications (1)

Application Number Title Priority Date Filing Date
NO961536A NO961536L (en) 1993-10-19 1996-04-18 Preparation of bisphosphonates and growth hormone secretagogue

Country Status (16)

Country Link
EP (1) EP0813414A4 (en)
JP (1) JPH09504525A (en)
KR (1) KR960705575A (en)
CN (1) CN1136278A (en)
AU (1) AU8083694A (en)
BG (1) BG100517A (en)
BR (1) BR9407869A (en)
CA (1) CA2173333A1 (en)
CZ (1) CZ109196A3 (en)
FI (1) FI961681A7 (en)
HU (1) HUT75224A (en)
LV (1) LV11432B (en)
NO (1) NO961536L (en)
PL (1) PL314003A1 (en)
SK (1) SK49796A3 (en)
WO (1) WO1995011029A1 (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US20020111461A1 (en) 1999-05-21 2002-08-15 Todd C. Somers Low molecular weight peptidomimetic growth hormone secretagogues
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
ATE288444T1 (en) * 1995-05-29 2005-02-15 Pfizer DIPEPTIDES THAT STIMULATE THE RELEASE OF GROWTH HORMONES
CA2234817A1 (en) * 1995-10-27 1997-05-01 Mandana Asgharnejad Wet granulation formulation of a growth hormone secretagogue
EP0870199B1 (en) 1995-12-13 2006-07-26 Merck & Co., Inc. Assays for growth hormone secretagogue receptors
US6531314B1 (en) 1996-12-10 2003-03-11 Merck & Co., Inc. Growth hormone secretagogue receptor family
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (en) * 1996-02-28 1997-06-26 Inc Pfizer COMBINED THERAPY FOR OSTEOPOROSIS
KR20000016204A (en) * 1996-05-31 2000-03-25 한센 핀 베네드, 안네 제헤르 Growth hormone component and bone anti-absorptive agent in cyclic (coherence) treatment of osteoporosis
WO1998018815A1 (en) * 1996-10-25 1998-05-07 Merck & Co., Inc. Convergent process for the preparation of a growth hormone secretagogue
US6376477B2 (en) 1996-11-25 2002-04-23 Merck & Co., Inc. Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
ZA987385B (en) * 1997-08-19 2000-04-18 Lilly Co Eli Growth hormone secretagogues.
US6211174B1 (en) * 1997-10-31 2001-04-03 Merck & Co., Inc. Naphtho-fused lactams promote release of growth hormone
IT1296495B1 (en) * 1997-11-21 1999-06-25 Prodotti Antibiotici Spa USE OF BISPHOSPHONATES IN THE PREPARATION OF PHARMACEUTICAL FORMS FOR INTRAMUSCULAR ADMINISTRATION
US6682908B1 (en) 1998-07-10 2004-01-27 Merck & Co., Inc. Mouse growth hormone secretagogue receptor
JP2002520011A (en) 1998-07-13 2002-07-09 メルク・アンド・カンパニー・インコーポレーテッド Growth hormone secretagogue-related receptors and nucleic acids
JP2002522058A (en) 1998-08-10 2002-07-23 メルク・アンド・カンパニー・インコーポレーテッド Canine growth hormone secretagogue receptor
EP1112071A4 (en) * 1998-08-18 2003-03-19 Lilly Co Eli Growth hormone secretagogues
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
AR013994A1 (en) * 1998-10-30 2001-01-31 Gador Sa PROCEDURE AND PREPARATIONS THAT SELECTIVELY MODULATE THE FUNCTION OF THE OSTEOBLASTO FOR THE PREVENTION AND TREATMENT OF FRAGILIZING OSTEOPATHIES.
AU1525700A (en) * 1998-11-19 2000-06-05 Board Of Trustees Of The University Of Arkansas, The Increasing bone strength with selected bisphosphonates
US6828331B1 (en) 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
EP1188441A4 (en) * 1999-06-02 2004-01-28 Procter & Gamble ORAL PREPARATIONS OF DISODIUM ETIDRONATE
ATE446758T1 (en) 2000-05-31 2009-11-15 Pfizer Prod Inc USE OF GROWTH HORMONE SECRETAGOGENES TO PROMOTE DIGESTIVE MOTILITY
US6548042B2 (en) 2000-08-07 2003-04-15 Arstad Erik Bis-phosphonate compounds
US7560490B2 (en) * 2001-01-23 2009-07-14 Gador S.A. Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof
US7125840B2 (en) 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
US7396846B2 (en) 2002-04-09 2008-07-08 Eli Lilly And Company Growth hormone secretagogues
GB0213715D0 (en) 2002-06-14 2002-07-24 Syngenta Ltd Chemical compounds
ES2394782T3 (en) * 2003-05-07 2013-02-05 Osteologix A/S Composition with strontium and vitamin D for the prophylaxis and / or treatment of cartilage and / or bone conditions
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
TW200621244A (en) 2004-08-19 2006-07-01 Vertex Pharma Modulators of muscarinic receptors
US7786141B2 (en) 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
JP2008521825A (en) 2004-11-29 2008-06-26 バーテックス ファーマシューティカルズ インコーポレイテッド Muscarinic receptor modulators
US7858635B2 (en) 2005-12-22 2010-12-28 Vertex Pharmaceuticals Incorporated Spiro compounds as modulators of muscarinic receptors
NZ570497A (en) 2006-02-22 2011-09-30 Vertex Pharma Spiro condensed 4,4'-quinilino-piperidines derivatives as modulators of muscarinic receptors
CN101426499A (en) 2006-02-22 2009-05-06 弗特克斯药品有限公司 Modulators of muscarinic receptors
CU23558A1 (en) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech COMPOUNDS ANALOG TO THE PEPTIDIC SECRETAGOGS OF THE GROWTH HORMONE
CN101500565A (en) 2006-06-29 2009-08-05 弗特克斯药品有限公司 Modulators of muscarinic receptors
EP2051712A2 (en) 2006-08-15 2009-04-29 Vertex Pharmceuticals Incorporated Modulators of muscarinic receptors
WO2008021545A2 (en) 2006-08-18 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
KR20090107088A (en) 2007-02-09 2009-10-12 트랜자임 파르마 인크 Macrocyclic ghrelin receptor modulators and methods of using the same
EP2155769B1 (en) 2007-05-04 2012-06-27 Katholieke Universiteit Leuven KU Leuven Research & Development Tissue degeneration protection
MX2010003373A (en) 2007-10-03 2010-04-30 Vertex Pharma Modulators of muscarinic receptors.
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
SG11201609050UA (en) 2014-05-30 2016-12-29 Pfizer Carbonitrile derivatives as selective androgen receptor modulators
CA3100276A1 (en) 2018-06-06 2019-12-12 Massachusetts Institute Of Technology Circular rna for translation in eukaryotic cells
WO2020237227A1 (en) 2019-05-22 2020-11-26 Massachusetts Institute Of Technology Circular rna compositions and methods
AU2020397956A1 (en) 2019-12-04 2022-07-07 Orna Therapeutics, Inc. Circular RNA compositions and methods
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU568433B2 (en) * 1984-04-30 1987-12-24 Procter & Gamble Company, The Treating osteoporosis
AU569391B2 (en) * 1984-04-30 1988-01-28 Procter & Gamble Company, The Treating osteoporosis
NZ258412A (en) * 1992-12-11 1997-01-29 Merck & Co Inc Spiro-fused piperidine derivatives and pharmaceutical compositions
US5284841A (en) * 1993-02-04 1994-02-08 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5434261A (en) * 1993-07-26 1995-07-18 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5545735A (en) * 1993-10-04 1996-08-13 Merck & Co., Inc. Benzo-Fused Lactams promote release of growth hormone

Also Published As

Publication number Publication date
BR9407869A (en) 1996-10-29
NO961536D0 (en) 1996-04-18
EP0813414A1 (en) 1997-12-29
CA2173333A1 (en) 1995-04-27
PL314003A1 (en) 1996-08-05
AU8083694A (en) 1995-05-08
FI961681A0 (en) 1996-04-17
CZ109196A3 (en) 1996-10-16
HUT75224A (en) 1997-04-28
KR960705575A (en) 1996-11-08
LV11432B (en) 1996-12-20
BG100517A (en) 1996-11-29
EP0813414A4 (en) 1999-07-21
LV11432A (en) 1996-08-20
SK49796A3 (en) 1997-05-07
JPH09504525A (en) 1997-05-06
FI961681L (en) 1996-06-12
WO1995011029A1 (en) 1995-04-27
CN1136278A (en) 1996-11-20
HU9601013D0 (en) 1996-06-28
FI961681A7 (en) 1996-06-12

Similar Documents

Publication Publication Date Title
NO961536L (en) Preparation of bisphosphonates and growth hormone secretagogue
AU3022692A (en) Methods for the treatment of osteoporosis using bone-active phosphonates and parathyroid hormone
AU8904491A (en) Foot and leg splint device
DE69527672D1 (en) Brace for correcting the foot and footwear with this brace
AU2905592A (en) Foot orthosis and method
AU6094096A (en) Use of gamma-hydroxybutyrate for the stimulation of sleep-re lated growth hormone secretion
IT8819961A0 (en) MODULAR COMPOSITE PROSTHETIC DEVICE FOR LEG AND FOOT.
EP0741578A4 (en) HUMAN GROWTH HORMONE
DE69418504D1 (en) Double fixation prosthesis
DK487587A (en) FLUORED AND CALCIUM AGENTS WITH DELAYED DELIVERY
IL101587A0 (en) Biologically active peptide composition and uses therefor
ZA936692B (en) Physiologically active peptide composition
AU9084191A (en) Use of angiotensin ii receptor antagonists in the treatment of hemorragic stroke
ZA941199B (en) Physiologically active compound HS-1 and process for the preparation of the same
AU9052991A (en) Use of angiotensin ii antagonist in the treatment of infarction
NO167146C (en) ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE CONDENSED DIAZEPINONES.
NO165493C (en) ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE CHINAZOL INDIA AND PYRIDOPYRIMID INDIA.
NO168477C (en) ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE CONDENSED DIAZEPINONES.
NO960545D0 (en) Treatment of adverse effects associated with the administration of extracellular hemoglobin
NO921086D0 (en) PROCEDURE FOR THE PREPARATION AND USE OF SUBSTITUTED 2 ', 3'-DIDESOXY-5-TRIFLUORMYTYLURIDINES
NO903939L (en) ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE CONDENSED DIAZEPINONES.
ES2094930T3 (en) NEW TROMBINE INHIBITING PROTEIN ISOLATED FROM TICKS.
EP0540575A4 (en) Human meg-csf protein and methods
AU9056191A (en) Foot warmer insole and method
IL86156A0 (en) Preparation of l-phenylalanine with the aid of recombinant bacteria